Articles On Telix Pharmaceuticals (ASX:TLX)

Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)? You're not alone! The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to st...

Australian shares opened with a 0.2% increase driven by gains in mining sectors like iron ore, lithium, and coal, although this was tempered by weaknesses in healthcare and technology. Key mining players such as Fortescue and BHP experience...

ASX investors woke today to news that the European Central Bank had cut interest rates. In a broadly expected move, the ECB lowered the official interest rate by 0.25%, taking it from 4.00% to 3.75%. This marks the first easing by the ECB s...

Given June is upon us, so too is tax time… along with the moons and Ferris wheels. It's natural for Australians to be thinking about any dollars they can save when they lodge their next tax return at this time of year. To indulge this admir...

S&P/ASX 200 Index (ASX: XJO) investors hoping for interest rate relief from the Reserve Bank of Australia are eyeing the overnight announcement from the Bank of Canada. In a move that was widely expected, the Bank of Canada cut the nat...

The European Lithium Ltd (ASX: EUR) share price has been a strong performer on Thursday. At the time of writing, the ASX lithium stock is up 12% to 5.6 cents. This is despite many of its peers, such as Core Lithium Ltd (ASX: CXO), tumbling...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has caught the eye of investors on Thursday. In morning trade, the radiopharmaceuticals company's shares surged over 6% to a record high of $19.06. Telix's shares have since pulled back b...

By Rudi Filapek-Vandyck, EditorSo far this year, ResMed ((RMD)) shares are down -4.4%, with Cochlear ((COH)) shares down -0.8% and CSL ((CSL)) scraping into positive territory to the tune of 1.2%Doesn't sound like much? Always good to know...

Morgan Stanley and Jefferies are among the managers overseeing Telix Pharma’s (ASX:TLX) freshly commenced US IPO process to raise $300M and list on the NASDAQ. First announced in mid-late May, Telix will offer American Depositary Shares...

The Australian market is tipped to open higher this morning, with futures up 52.3 points at 8:49 AEST, mainly riding on a rally in the United States which saw the S&P 500 and Nasdaq bourses close at record highs. On Wednesday in the...

By Tim Boreham, Editor, The New Criterion ASX code: ((ATX)) Market cap: $17.93m Shares on issue: 271,609,233 Chief executive officer: Dr Chris Burns (co-founder) Board: Dr Warwick Tong (chair), Dr Burns, Dr Robert Peach, Jane Bell Financial...

Overseas markets rallied in May on lower bond yields and stabilising inflation prints, but the Australian market couldn't sustain the early May up-swing, weighed down by a surprisingly high April CPI reading and some negative earnings updat...

Wealth Within analyst Filip Tortevski has been eyeing some big gun miners whose stock has been falling for a while now, contemplating the historic value of blue chips which tend to rebound spectacularly when the market improves. None of...

Aus shares began the session with minimal change, leveling off shortly after the market opened. This stagnation was attributed to a decline in commodity prices, which adversely affected mining firms, counterbalancing any positive momentum i...

The big news in shares vs. property is Brisbane overtaking Canberra as Australia's second-most expensive city, with the median home value in the Sunshine State's capital rising 1.4% last month. The last time Brisbane was the second high...

Three S&P/ASX 200 Index (ASX: XJO) stocks did more than their fair share of the heavy lifting in May. The month just past saw the ASX 200 close up 0.5% at 7,701.7 points. But these three companies left those gains far behind. Which com...

INOVIQ’s exosomes therapy to target breast cancer cells INOVIQ (ASX:IIQ) said it has created specialised exosomes (EEVs) designed to target and destroy breast cancer cells in a lab setting. Using a special protein called a chimeric antigen...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has bounced back into the green today. Shares in the S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company closed up 15.3% on Friday trading for $18.15 apiece. At the time of wri...

What grabbed the headlines last week?   Major global share markets fell over the last week, as higher bond yields weighed. We also learned that, in America, a convicted felon can totally run for president. The current pres might need to pi...

The S&P/ASX 200 Index (ASX: XJO) had a relatively decent time in May. During the month, the benchmark index rose by 0.5% to end the period at 7,701.7 points. While that was positive, a number of ASX 200 shares smashed the market with s...

Melbourne-based Telix Pharmaceuticals Ltd (ASX:TLX) has reported that data from recent tests on TLX591 – therapy targeted at treatment of specific forms of prostate cancer – reveal that people can live with the disease without it getting wo...

The ASX200 is trading up around 0.55% With strong performances from major medical companies, the healthcare sector is leading gains, up 1.2%, Discretionary follows, up nearly a per cent. IT is the only sector to fall into the red, dow...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.55% to 7,670 points. Four ASX shares that are rising more than most today are li...

FDA approves AVITA’s RECELL GO System Wound care medical company, AVITA Medical ASX:AVH), surged +13% this morning after receiving an FDA approval for its latest product, the RECELL GO System. The RECELL GO system basically harvests a small...

31 May 2024 - A snapshot of the stocks on the move, featuring Telix Pharmaceuticals (ASX:TLX), AVITA Medical (ASX:AVH) and EZZ Life Science (ASX:EZZ).

At 11:30am, the S&P/ASX 200 is 0.49 per cent higher at 7,665.70, following a three-day sell-off, driven by broad buying spurred by slightly elevated April inflation data. Meanwhile, in New York, tech stocks declined as US consumer spend...

  To register for today's webinar click here. Telix Pharmaceuticals (ASX:TLX) announces additional positive data from the ProstACT SELECT trial of TLX591. TLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company closed yesterday at $15.74. At the time of writing, shares are trading 10.6% higher at...

The ASX200 is set to rise by +0.80% on Friday following a lacklustre week for the bourse. The USA’s latest GDP growth data for Q1 came in overnight cooler than expected. The United States logged growth of 1.3% in the first three mont...

ASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial results and strong investor interest are propelling the sector forward. Plenty of upcoming catalysts and company-specific developments could...

In this week’s video insight, I discuss the remarkable progress of Telix Pharmaceuticals (ASX:TLX). Over the past ten months, Telix’s share price has seen significant growth, driven by advancements in radiation imaging and therapy technolog...

In this week’s video insight, I discuss the remarkable progress of Telix Pharmaceuticals (ASX:TLX). Over the past ten months, Telix’s share price has seen significant growth, driven by advancements in radiation imaging and therapy technolog...

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

Telix Pharmaceuticals has submitted a new drug application to the United States Food and Drug Administration for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer. Telix said subject t...

Telix (ASX:TLX) has announced the successful completion of CUPID, a first-in-human Phase 1 dose escalation study of TLX592 in patients with advanced prostate cancer.

I had the pleasure of joining Adam Keily on the ‘Equity Mates’ podcast, where we had a great discussion about ten noteworthy stocks that are currently catching my eye. These picks span across a variety of sectors, domestic and global and in...

The ASX200 slipped into the red at close, 0.05 of a per cent down with industrials gaining 0.49% and IT 0.27% doing the heavy lifting offset by communications limping over the line, shedding -2.5%. In the green Webjet (ASX:WEB) shot u...

It was a wild day for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Wednesday. After taking a bath yesterday, the ASX 200 had a strong start this mor...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain on Wednesday. In afternoon trade, the benchmark index is up 0.1% to 7,858.8 points. Four ASX shares that are rising more than most today are listed below. Here's why...

Seven S&P/ASX 200 Index (ASX: XJO) shares are leaping to 52-week highs today. Yep, seven! Their strong performance is helping lift the benchmark index 0.3% in early afternoon trade. Any guesses? Keep those in mind and read on. ASX 200...

The ASX200 closed just 12 points down (0.15%) as the local markets shrugged off another record close for the NASDAQ on Monday night. The IT and industrials sectors were strongest, both gaining just shy of 0.75%. Telecommunications fel...

It’s been a busy day at the Australian Energy Producers conference in Perth, where the morning’s guest speakers included resources minister Madeleine King and Woodside’s Meg O’Neill inside and several hundred protesters outside.  Apart f...

Telix says TLX592 is effective on prostate cancer Telix Pharmaceuticals (ASX:TLX) has today announced the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer. Th...

The Reserve Bank's May policy meeting minutes indicated that while raising the cash rate was considered if forecasts risked optimism regarding inflation factors, stronger-than-expected data prompted them to maintain the rate at 4.35%, citin...

The ASX200 closed around 0.63% up with energy soaring 2.3% and materials 1.9%. The poorest performer was healthcare – down 0.8%. In the green The Star Entertainment Group (ASX:SGR) shot up 20% on news it’s received interest fro...

The ASX200 is up 0.65% – in line with futures’ predictions.  Healthcare is down 0.4% – whilst materials is up 1.96% and energy 1.79% mid-session. The materials sector is having a strong run mid-session; Rio Tinto (ASX:RIO), Fortescue...

Telix Pharmaceuticals (ASX:TLX) announced on Monday it has filed early-stage paperwork proposing to US regulators a listing on the American equities markets. Morgan Stanley and Jefferies are among the firms acting as managers for the IPO...

Given the topic, let's try to keep this article as light-hearted as possible. Let's assume that one day, out of the blue, you get a call from a lawyer telling you that your mysterious great aunt Holga recently passed away at the ripe old ag...

Bell Potter says biotech very much a non-cyclical performer driven by catalysts including clinical trial data Radiopharmaceutical-focused Clarity Pharmaceuticals has risen 76% YTD after promising trial results Merchant Funds is bullish on...

Two ASX shares that have made their shareholders smile this year are DroneShield Ltd (ASX: DRO) and Telix Pharmaceuticals Ltd (ASX: TLX). Since the start of the year, their shares have risen by approximately 120% and 50%, respectively. As a...